Page 200 - Read Online

Zhao et al. Hepatoma Res 2019;5:17 Hepatoma Research
DOI: 10.20517/2394-5079.2018.116

Original Article Open Access

Efficacy and safety of stereotactic body
radiation therapy combined with transarterial

chemoembolization for Chinese intermediate-to
advanced-stage hepatocellular carcinoma patients:

a systematic review and meta-analysis

Shou-Jie Zhao , Bai-Shu Dai , Zhong-Jun Shao , Xi-Lin Du , Wei-Lu Zhang , Yong Long 2,#
2
1
2,#
1,#
1
1 Department of General Surgery, Tangdu Hospital of the Fourth Military Medical University, Xi’an 710038, China.
2 Department of Epidemiology, the Fourth Military Medical University, Xi’an 710032, China.
# The authors contributed equally.
Correspondence to: Dr. Yong Long and Dr. Wei-Lu Zhang, Department of Epidemiology, the Fourth Military Medical University,
No. 169 Changle west road, Xi’an 710032, China. E-mail: longyong@fmmu.edu.cn; zhangweilu@126.com; Dr. Xi-Lin Du,
Department of General Surgery, Tangdu Hospital of the Fourth Military Medical University, No. 569 Xinsi Road, Xi’an 710038,
China. E-mail: dxlin0705@163.com
How to cite this article: Zhao SJ, Dai BS, Shao ZJ, Du XL, Zhang WL, Long Y. Efficacy and safety of stereotactic body radiation
therapy combined with transarterial chemoembolization for Chinese intermediate-to advanced-stage hepatocellular carcinoma
patients: a systematic review and meta-analysis. Hepatoma Res 2019;5:17. http://dx.doi.org/10.20517/2394-5079.2018.116

Received: 27 Dec 2018 First Decision: 27 Feb 2019 Revised: 16 May 2019 Accepted: 16 May 2019 Published: 22 May 2019
Science Editor: Guang-Wen Cao Copy Editor: Cai-Hong Wang Production Editor: Jing Yu

Abstract
Aim: According to the current guidelines, transarterial chemoembolization (TACE) remains the first-line therapies
for hepatocellular carcinoma (HCC) patients at Barcelona Clinic Liver Cancer (BCLC) B-stage and sorafenib is a
small molecule target drug for BCLC C-stage. In clinical practice, clinicians have attempted to use stereotactic body
radiation therapy (SBRT) plus TACE for treating intermediate- to advanced-stage HCC. However, the therapeutic
effects are still inconsistent. This meta-analysis was conducted to elucidate the validity and safety of the combination
therapy of SBRT plus TACE in the patients with intermediate-to advanced-stage HCC.

Methods: PubMed, MEDLINE, Web of Science, China Biology Medicine, Chinese Knowledge resources integrated
and Chinese Scientific Journal Full-Text Database was searched from their inception date to November 2018. The
survival rates (half-year, one-year and two-year) were analyzed and compared between the observation groups and
the control groups. The negative conversion rate of AFP and the total effective rate were also assessed. Risk ratios
(RR) and 95%CI were calculated to express therapeutic effects.

© The Author(s) 2019. Open Access This article is licensed under a Creative Commons Attribution 4.0
International License (https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use,
sharing, adaptation, distribution and reproduction in any medium or format, for any purpose, even commercially, as long
as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license,
and indicate if changes were made.

www.hrjournal.net